Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-03-29
DOI
10.3389/fonc.2019.00194
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation
- (2018) L. Wang et al. AMERICAN JOURNAL OF TRANSPLANTATION
- HDAC11 is a regulator of diverse immune functions
- (2018) Cansu Yanginlar et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- The role of IDH mutations in acute myeloid leukemia
- (2018) Guillermo Montalban-Bravo et al. Future Oncology
- Enhancer of zeste homolog 2 (EZH2) inhibitors
- (2018) Nitya Gulati et al. LEUKEMIA & LYMPHOMA
- The DNMT3A R882H mutant displays altered flanking sequence preferences
- (2018) Max Emperle et al. NUCLEIC ACIDS RESEARCH
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
- (2018) Janeta Popovici-Muller et al. ACS Medicinal Chemistry Letters
- Histone methylation in DNA repair and clinical practice: new findings during the past 5-years
- (2018) Shuhua Wei et al. Journal of Cancer
- Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition
- (2018) Deshui Jia et al. Cancer Discovery
- The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer
- (2017) Fabio Ciccarone et al. SEMINARS IN CANCER BIOLOGY
- Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
- (2016) D. Morel et al. ANNALS OF ONCOLOGY
- IDH mutations in cancer and progress toward development of targeted therapeutics
- (2016) L. Dang et al. ANNALS OF ONCOLOGY
- DOT1L as a therapeutic target for the treatment of DNMT3A -mutant acute myeloid leukemia
- (2016) Rachel E. Rau et al. BLOOD
- DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1
- (2016) Jie Xu et al. Journal of Hematology & Oncology
- DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
- (2016) Olga A Guryanova et al. NATURE MEDICINE
- An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
- (2016) George P Souroullas et al. NATURE MEDICINE
- DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation
- (2016) Junji Koya et al. Nature Communications
- CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
- (2016) Yanwen Jiang et al. Cancer Discovery
- Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation
- (2015) Zheng Zhou et al. LEUKEMIA & LYMPHOMA
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
- (2015) H J Ferreira et al. ONCOGENE
- Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
- (2015) L. Goyal et al. ONCOLOGIST
- Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth
- (2015) Anthony M. Barsotti et al. Oncotarget
- IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
- (2015) Philipp Kickingereder et al. Scientific Reports
- 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
- (2015) Alexandra Borodovsky et al. Oncotarget
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Persistence ofDNMT3Amutations at long-term remission in adult patients with AML
- (2014) Gro G. Pløen et al. BRITISH JOURNAL OF HAEMATOLOGY
- The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers
- (2014) David A. Russler-Germain et al. CANCER CELL
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
- (2014) Supriya K. Saha et al. NATURE
- Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability
- (2014) Katrina Tatton-Brown et al. NATURE GENETICS
- DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells
- (2014) J. Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Driver mutations of cancer epigenomes
- (2014) David M. Roy et al. Protein & Cell
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
- EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non-Small Cell Lung Carcinoma
- (2013) C. Behrens et al. CLINICAL CANCER RESEARCH
- IDH1 and IDH2 Mutations in Gliomas
- (2013) Adam L. Cohen et al. Current Neurology and Neuroscience Reports
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Epigenetic regulation and cancer (Review)
- (2013) Q.W. CHEN et al. ONCOLOGY REPORTS
- A687V EZH2 is a gain-of-function mutation found in lymphoma patients
- (2012) Christina R. Majer et al. FEBS LETTERS
- Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
- (2012) Benjamin R. Kipp et al. HUMAN PATHOLOGY
- Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance
- (2012) Yuejun Fu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
- (2011) Yuejun Fu et al. BIOTECHNOLOGY LETTERS
- IDH mutation status in prostate cancer
- (2011) A F Ghiam et al. ONCOGENE
- Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice
- (2011) M. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Array-based genomic resequencing of human leukemia
- (2010) Y Yamashita et al. ONCOGENE
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IDH mutations in glioma and acute myeloid leukemia
- (2010) Lenny Dang et al. TRENDS IN MOLECULAR MEDICINE
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1α
- (2008) Patrick J. Pollard et al. BIOCHEMICAL JOURNAL
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started